Navigation Links
New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
Date:6/28/2010

recommended blood pressure target was greater with the triple combination therapy (40/10/25 mg) versus corresponding dual combination therapy regardless of gender, age, race, and hypertension severity (P<0.0001).(7)

Safety & Tolerability

Across all groups, drug-related treatment adverse events (TEAEs) were reported in 25.4 percent of patients.(1)  Most TEAEs and drug-related TEAEs were mild or moderate in severity.(1) More discontinuations due to TEAEs occurred in the olmesartan medoxomil / amlodipine / hydrochlorothiazide (40/10/25 mg) (4.0 percent) versus the dual combination therapy groups (1.0 to 2.1 percent) and were due to adverse events such as dizziness and hypotension.(1) These discontinuations can potentially be attributed to the more pronounced pharmacodynamic effect of the triple combination therapy.(1) Peripheral edema also was a cause for discontinuation.(1)

In addition, discontinuations for patients on triple combination therapy also included subjects who experienced an adverse event on earlier treatment (i.e. placebo or dual), prior to initiation of the triple combination regimen.(1)

About The Triple Combination Therapy

A fixed-dose, single combination product of olmesartan medoxomil/ amlodipine / hydrochlorothiazide is currently under review for approval with the US Food and Drug Administration (FDA) for the treatment of hypertension.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engag
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week
2. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
3. Highmark Study Shows Integrated Medical and Pharmacy Benefits Lower Costs, Promote Better Health
4. New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes
5. Drug in New Class of Targeted Therapies Shows Early Promise Against Blood-Related Cancers
6. New Study Shows ENJUVIA® Significantly Reduced Sleep Time Awakenings Caused by Hot Flashes in Postmenopausal Women
7. Implanted Sleep Device Shows Promising Early Results
8. Data Shows Ambulance Fees Will Deter Emergency Calls for Help
9. New Study Shows 84 Percent Reduction in Post-Cesarean Section Infections Through Comprehensive Prevention Strategy
10. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
11. Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... , HARBIN, China, Nov. 17 /PRNewswire-Asia-FirstCall/ ... Company") (Nasdaq: CSKI ), a,leading fully integrated pharmaceutical company in ... the third quarter,of 2009. , , Third Quarter ... to $43.2 million, -- Gross profit increased 44.8% ...
... Mass., Nov. 17 Decision Resources, one of the world,s ... finds that, driven by the continued dominance of opioids that ... cancer pain drug market will increase from $2.3 billion in ... France, Germany, Italy, Spain, the United Kingdom and Japan. , ...
Cached Medicine Technology:China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 2China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 3China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 4China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 5China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 6China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 7China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 8China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 9China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 10The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018 2
(Date:4/24/2014)... corresponding terminology, and the relevance of palliation in ... on randomized controlled trials (RCTs). This is the ... for Quality and Efficiency in Health Care (IQWiG), ... , Together with external experts, IQWiG analysed studies ... cancer, malignant melanoma, and pancreatic cancer. For this ...
(Date:4/24/2014)... more than one out of three survivors of ... in The Lancet Respiratory Medicine , and ... rather than mentally. , It is one of ... and functional outcomes of critical care survivors, according ... of Medicine, and it highlights a significant public ...
(Date:4/24/2014)... team of researchers was the first in the world ... a tumour of the jaw. , Ameloblastoma is an ... treatment. Ameloblastoma is most often found in the posterior ... often resulting in tissue deficiencies in the jaws as ... therapy could reduce the need for surgery and the ...
(Date:4/24/2014)... University researcher has found a relationship between motor skill ... spectrum disorder in very young children. , The ... a direct relationship between motor skills and autism severity, ... should be included in treatment plans for young children ... OSU,s College of Public Health and Human Sciences. ...
(Date:4/24/2014)... 2009 the influenza pH1N1 virus caused the first flu ... in May 2009 and killed more than 50 people ... Finns mainly during flu epidemics (winter/spring seasons). , ... serious complicated illnesses. World Health Organization has recommended Tamiflu ... The disadvantage of this drug is that it targets ...
Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
... Goodman Steps Down; John Walker, Board Chair, Named Executive ... ... Renovis,Inc. (Nasdaq: RNVS ), a biopharmaceutical company focused on the ... and inflammatory diseases, today announced that Corey Goodman,Ph.D., will step down today ...
... approve gastric band for adolescents by 2009, WALTHAM, ... gastric band market, currently valued at over $190,million, will ... approval,of the LAP-BAND device for adolescents aged 14 to ... of the most rapidly growing,segments of the obese population, ...
... Concentra was recently announced,as a silver ... Awards, sponsored by,ComPsych Corporation. Concentra was selected ... participation rates,and achieved results. Concentra, a ... for its commitment to better health and ...
... Oct. 1 Mylan Laboratories Inc.,(NYSE: MYL ) ... Vice,President and Treasurer, effective October 22, 2007. Mr. Byala ... with responsibility for,treasury planning in both New York and ... in various treasury positions of increasing responsibility.,Prior to Pfizer, ...
... Inc., a leader,in healthcare payment and cost management ... Inc. for $54 million, consisting of $44,million in ... common,stock. The acquisition will expand Viant,s PPO network ... existing lines of services to the,nation,s leading health ...
... LeMaitre Vascular,Inc., (Nasdaq: LMAT ), a provider ... has reached an agreement to launch a,direct sales force ... sells its products in Italy through an,exclusive distribution agreement ... to terminate Serom,s exclusive rights on,January 25, 2008 in ...
Cached Medicine News:Health News:Renovis Announces Management Changes 2Health News:Renovis Announces Management Changes 3Health News:Renovis Announces Management Changes 4Health News:Renovis Announces Management Changes 5Health News:The Skinny on Teen Surgery 2Health News:Concentra Honored With Silver Health at Work(SM) Award by ComPsych(R) Corp. 2Health News:Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer 2Health News:Viant Acquires Texas True Choice 2Health News:LeMaitre Vascular to Start Italian Sales Force 2Health News:LeMaitre Vascular to Start Italian Sales Force 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: